Message from the Guest Editor

Dear Colleagues,

In line with numerous other therapeutic agents, the success of cancer drugs is hindered by the development of clinical drug resistance. The scientific community has mounted a considerable effort in order to understand the underlying mechanisms associated with anticancer drug resistance, over a number of decades. These lines of enquiries have resulted in an enrichment of our knowledge of tumour cell biology—but still leave the oncologist with the day-to-day problem of clinical drug resistance.

The overall objective for the cancer scientist is to work hand in hand with the oncologist to find ways to predict in advance clinical drug resistance by the use of biomarker development and also to develop strategies to overcome overt drug resistance for example by the use of combination therapies.

Dr. Helen M. Coley
Guest Editor
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI